California-based Nivagen is continuing to raise money to push through a number of generic launches in the US this year, the company’s founder and chief Jay Shukla told Generics Bulletin.
North American generics specialist Nivagen Pharmaceuticals has secured an $8m credit facility with help from commercial finance advisors Business Capital, providing some of the firepower to launch almost 10 new generics this year.
The debt, which is secured on assets, will hand the firm “the necessary working capital to facilitate its growth as...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
